SKAN Group Valuation
Is SKAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SKAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SKAN (CHF78.8) is trading below our estimate of fair value (CHF93.91)
Significantly Below Fair Value: SKAN is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SKAN?
Other financial metrics that can be useful for relative valuation.
| What is SKAN's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CHF 1.77b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.3x |
| Enterprise Value/EBITDA | 35.4x |
| PEG Ratio | 3.3x |
Price to Earnings Ratio vs Peers
How does SKAN's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33.5x | ||
TECN Tecan Group | 30.9x | 9.2% | CHF 4.1b |
SFZN Siegfried Holding | 38x | 14.4% | CHF 4.3b |
BANB Bachem Holding | 51x | 18.5% | CHF 5.8b |
XLS Xlife Sciences | 14.1x | n/a | CHF 209.6m |
SKAN SKAN Group | 67.3x | 20.6% | CHF 1.8b |
Price-To-Earnings vs Peers: SKAN is expensive based on its Price-To-Earnings Ratio (67.3x) compared to the peer average (33.5x).
Price to Earnings Ratio vs Industry
How does SKAN's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Earnings vs Industry: SKAN is expensive based on its Price-To-Earnings Ratio (67.3x) compared to the European Life Sciences industry average (40.7x).
Price to Earnings Ratio vs Fair Ratio
What is SKAN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 67.3x |
| Fair PE Ratio | 24.3x |
Price-To-Earnings vs Fair Ratio: SKAN is expensive based on its Price-To-Earnings Ratio (67.3x) compared to the estimated Fair Price-To-Earnings Ratio (24.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CHF 78.80 | CHF 97.50 +23.7% | 10.8% | CHF 108.00 | CHF 87.00 | n/a | 2 |
| Jul ’25 | CHF 79.60 | CHF 97.50 +22.5% | 10.8% | CHF 108.00 | CHF 87.00 | n/a | 2 |
| Jun ’25 | CHF 80.50 | CHF 95.67 +18.8% | 9.4% | CHF 108.00 | CHF 87.00 | n/a | 3 |
| May ’25 | CHF 81.80 | CHF 91.33 +11.7% | 15.2% | CHF 108.00 | CHF 74.00 | n/a | 3 |
| Apr ’25 | CHF 85.10 | CHF 91.33 +7.3% | 15.2% | CHF 108.00 | CHF 74.00 | n/a | 3 |
| Mar ’25 | CHF 82.10 | CHF 91.33 +11.2% | 15.2% | CHF 108.00 | CHF 74.00 | n/a | 3 |
| Feb ’25 | CHF 75.60 | CHF 91.33 +20.8% | 15.2% | CHF 108.00 | CHF 74.00 | n/a | 3 |
| Jan ’25 | CHF 80.80 | CHF 91.33 +13.0% | 15.2% | CHF 108.00 | CHF 74.00 | n/a | 3 |
| Dec ’24 | CHF 78.20 | CHF 91.33 +16.8% | 15.2% | CHF 108.00 | CHF 74.00 | n/a | 3 |
| Nov ’24 | CHF 69.90 | CHF 91.33 +30.7% | 15.2% | CHF 108.00 | CHF 74.00 | n/a | 3 |
| Oct ’24 | CHF 77.80 | CHF 91.00 +17.0% | 18.7% | CHF 108.00 | CHF 74.00 | n/a | 2 |
| Sep ’24 | CHF 79.40 | CHF 92.33 +16.3% | 15.2% | CHF 108.00 | CHF 74.00 | n/a | 3 |
| Aug ’24 | CHF 79.80 | CHF 100.50 +25.9% | 5.5% | CHF 106.00 | CHF 95.00 | CHF 79.30 | 2 |
| Jul ’24 | CHF 77.00 | CHF 100.50 +30.5% | 5.5% | CHF 106.00 | CHF 95.00 | CHF 79.60 | 2 |
| Jun ’24 | CHF 80.50 | CHF 100.50 +24.8% | 5.5% | CHF 106.00 | CHF 95.00 | CHF 80.50 | 2 |
| May ’24 | CHF 86.20 | CHF 94.00 +9.0% | 12.8% | CHF 106.00 | CHF 82.00 | CHF 81.80 | 2 |
| Apr ’24 | CHF 83.70 | CHF 94.00 +12.3% | 12.8% | CHF 106.00 | CHF 82.00 | CHF 85.10 | 2 |
| Mar ’24 | CHF 69.10 | CHF 86.50 +25.2% | 22.5% | CHF 106.00 | CHF 67.00 | CHF 82.10 | 2 |
| Feb ’24 | CHF 68.80 | CHF 86.50 +25.7% | 22.5% | CHF 106.00 | CHF 67.00 | CHF 75.60 | 2 |
| Jan ’24 | CHF 63.00 | CHF 86.50 +37.3% | 22.5% | CHF 106.00 | CHF 67.00 | CHF 80.80 | 2 |
| Dec ’23 | CHF 67.60 | CHF 86.50 +28.0% | 22.5% | CHF 106.00 | CHF 67.00 | CHF 78.20 | 2 |
| Nov ’23 | CHF 60.90 | CHF 86.50 +42.0% | 22.5% | CHF 106.00 | CHF 67.00 | CHF 69.90 | 2 |
| Oct ’23 | CHF 57.80 | CHF 86.50 +49.7% | 22.5% | CHF 106.00 | CHF 67.00 | CHF 77.80 | 2 |
| Sep ’23 | CHF 57.90 | CHF 86.50 +49.4% | 22.5% | CHF 106.00 | CHF 67.00 | CHF 79.40 | 2 |
| Aug ’23 | CHF 53.60 | CHF 86.50 +61.4% | 22.5% | CHF 106.00 | CHF 67.00 | CHF 79.80 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.